Summarized by Masters of Longevity from Longevity Technology.
A look at a pharma–AI genetics partnership expanded to target cardiovascular disease, explaining the kind of research and discovery approach readers will find.
Key Takeaways
- Boehringer Ingelheim expanded its multi-year research and license agreement with Variant Bio to include cardiovascular disease targets.
- The deal could exceed $250 million in upfront, license, and milestone payments tied to progress and validations.
- Variant Bio will apply its Inference platform combining large language models, machine learning, and statistical genetics to prioritize genetically supported targets.
